Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells - PubMed (original) (raw)

Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells

H Nagumo et al. Am J Physiol Cell Physiol. 2000 Jan.

Free article

Abstract

In smooth muscle, a Rho-regulated system of myosin phosphatase exists; however, it has yet to be established whether Rho kinase, one of the downstream effectors of Rho, mediates the regulation of myosin phosphatase activity in vivo. In the present study, we demonstrate in permeabilized vascular smooth muscle cells (SMCs) that the vasodilator 1-(5-isoquinolinesulfonyl)-homopiperazine (HA-1077), which we show to be a potent inhibitor of Rho kinase, dose dependently inhibits Rho-mediated enhancement of Ca(2+)-induced 20-kDa myosin light chain (MLC(20)) phosphorylation due to abrogating Rho-mediated inhibition of MLC(20) dephosphorylation. By an immune complex phosphatase assay, we found that guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) stimulation of permeabilized SMCs caused a decrease in myosin phosphatase activity with an increase in the extent of phosphorylation of the 130-kDa myosin-binding regulatory subunit (MBS) of myosin phosphatase in a Rho-dependent manner. HA-1077 abolished both of the Rho-mediated events. Moreover, we observed that the pleckstrin homology/cystein-rich domain protein of Rho kinase, a dominant negative inhibitor of Rho kinase, inhibited GTPgammaS-induced phosphorylation of MBS. These results provide direct in vivo evidence that Rho kinase mediates inhibition of myosin phosphatase activity with resultant enhancement of MLC(20) phosphorylation in smooth muscle and reveal the usefulness of HA-1077 as a Rho kinase inhibitor.

PubMed Disclaimer

Cited by

Evolution of the Dearomative Functionalization of Activated Quinolines and Isoquinolines: Expansion of the Electrophile Scope.
Kischkewitz M, Marinic B, Kratena N, Lai Y, Hepburn HB, Dow M, Christensen KE, Donohoe TJ. Kischkewitz M, et al. Angew Chem Weinheim Bergstr Ger. 2022 Jul 4;134(27):e202204682. doi: 10.1002/ange.202204682. Epub 2022 May 13. Angew Chem Weinheim Bergstr Ger. 2022. PMID: 38505668 Free PMC article.
SIC50: Determining drug inhibitory concentrations using a vision transformer and an optimized Sobel operator.
Wang Y, Zhang W, Yip H, Qu C, Hu H, Chen X, Lee T, Yang X, Yang B, Kumar P, Lee SY, Casimiro JJ, Zhang J, Wang A, Lam KS. Wang Y, et al. Patterns (N Y). 2023 Feb 3;4(2):100686. doi: 10.1016/j.patter.2023.100686. eCollection 2023 Feb 10. Patterns (N Y). 2023. PMID: 36873901 Free PMC article.
Rho GTPase Signaling in Platelet Regulation and Implication for Antiplatelet Therapies.
Dandamudi A, Akbar H, Cancelas J, Zheng Y. Dandamudi A, et al. Int J Mol Sci. 2023 Jan 28;24(3):2519. doi: 10.3390/ijms24032519. Int J Mol Sci. 2023. PMID: 36768837 Free PMC article. Review.
RHOA Therapeutic Targeting in Hematological Cancers.
Santos JC, Profitós-Pelejà N, Sánchez-Vinces S, Roué G. Santos JC, et al. Cells. 2023 Jan 28;12(3):433. doi: 10.3390/cells12030433. Cells. 2023. PMID: 36766776 Free PMC article. Review.
Immunogenic Death of Hepatocellular Carcinoma Cells in Mice Expressing Caspase-Resistant ROCK1 Is Not Replicated by ROCK Inhibitors.
Naylor G, Julian L, Watson-Bryce S, Mullin M, Nibbs RJ, Olson MF. Naylor G, et al. Cancers (Basel). 2022 Nov 30;14(23):5943. doi: 10.3390/cancers14235943. Cancers (Basel). 2022. PMID: 36497425 Free PMC article.

Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells - PubMed (original) (raw)